{"id":1651,"date":"2018-10-24T22:58:39","date_gmt":"2018-10-24T21:58:39","guid":{"rendered":"https:\/\/tris.sambrownprojects.com\/tris-pharma-presents-results-from-two-clinical-studies-on-dyanavel-xr-at-the-largest-annual-meeting-of-child-and-adolescent-psychiatrists\/"},"modified":"2024-06-03T11:14:35","modified_gmt":"2024-06-03T10:14:35","slug":"tris-pharma-presents-results-from-two-clinical-studies-on-dyanavel-xr-at-the-largest-annual-meeting-of-child-and-adolescent-psychiatrists","status":"publish","type":"post","link":"https:\/\/www.trispharma.com\/tris-pharma-presents-results-from-two-clinical-studies-on-dyanavel-xr-at-the-largest-annual-meeting-of-child-and-adolescent-psychiatrists\/","title":{"rendered":"Tris Pharma Presents Results from Two Clinical Studies on Dyanavel\u00ae<\/sup> XR at the Largest Annual Meeting of Child and Adolescent Psychiatrists"},"content":{"rendered":"

MONMOUTH JUNCTION, NJ, October 24, 2018 \/ PRNewswire\/ – Tris Pharma, Inc. (Tris), a biopharmaceutical company focused on developing innovative products that deliver meaningful patient benefits, will present new data from two studies on DYANAVEL\u00a0XR (amphetamine) extended-release oral suspension, CII, at the 65th<\/sup> Annual Meeting of the American Academy of Child and Adolescent Psychiatry (AACAP) taking place in Seattle, Washington, October 22 to 27, 2018. AACAP is the largest international medical congress of child and adolescent psychiatrists.<\/p>\n

DYANAVEL XR is approved to treat children six years and older with Attention Deficit\/Hyperactivity Disorder (ADHD). Please see important safety information for DYANAVEL\u00a0XR, including Boxed Warning about Abuse and Dependence, below.<\/p>\n

The two posters, to be presented on October 24, are:<\/p>\n

1) \u201cSingle Dose Pharmacokinetics of Amphetamine Extended-Release <\/em>Tablet (AMPH ER TAB) Compared with Amphetamine Extended-Release Oral Suspension (AMPH EROS)\u201d <\/em>and<\/p>\n

2) \u201cOpen-Label Dose Optimization Study of an Amphetamine Extended Release Oral Suspension in Children with Attention Deficit\/Hyperactivity Disorder.\u201d<\/em><\/p>\n

“These presentations underscore our commitment to furthering knowledge about and advancing research into the unmet needs of children and adolescents with ADHD,\u201d said Barry K. Herman, M.D., M.M.M., Tris\u2019 Chief Medical Officer.<\/p>\n

About ADHD<\/strong><\/p>\n

ADHD is one of the most common neurodevelopmental disorders characterized by an ongoing pattern of inattention and\/or hyperactivity and impulsivity. These behaviors can interfere with functioning or development. According to the Centers for Disease Control and Prevention\u2019s 2011 data, 11 percent of children aged four to 17 years in the U.S. have received an ADHD diagnosis at some point in their life.<\/p>\n

INDICATION <\/strong><\/p>\n

DYANAVEL\u00ae XR (amphetamine) extended-release oral suspension is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).<\/p>\n

IMPORTANT SAFETY INFORMATION <\/strong><\/p>\n\n\n\n
\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0WARNING: ABUSE AND DEPENDENCE<\/strong><\/p>\n

CNS stimulants, including DYANAVEL XR, other amphetamine-containing products, and methylphenidate, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence while on therapy.<\/strong><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n